Ferrari leads during night at Le Mans

Benedetto Vigna Chief Executive Officer Ferrari N.V.
Benedetto Vigna Chief Executive Officer - Ferrari N.V.
0Comments

The 24 Hours of Le Mans saw Ferrari emerge as key players during the night-time phase of the race. The three cars from the Prancing Horse manufacturer, including two 499Ps from the Ferrari – AF Corse team and a yellow-liveried entry from AF Corse, advanced to leading positions after four hours.

As evening descended, these Ferrari Hypercars maintained their positions among the front-runners, demonstrating effective strategy both on track and in pit stops. By sunrise, with six hours left in this 93rd edition of the race, car number 51 led the provisional standings. Antonio Giovinazzi, James Calado, and Alessandro Pier Guidi shared driving duties for this car.

Following closely behind was car number 83, just 6.744 seconds adrift. This crew included Robert Kubica, Phil Hanson, and official driver Yifei Ye. Rounding out the virtual podium was car number 50 with drivers Nicklas Nielsen, Antonio Fuoco, and Miguel Molina.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.